AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20574412 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent human papillomavirus vaccine (QHPV)
Number of subjects: 126
Study 20574412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 18664696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT) package for social anxiety
Number of subjects: 32
Study 18664696 — intervention group
Group type: COMPARATOR
Intervention: Speech restructuring treatment alone
Number of subjects: 32
Study 17057794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin 0.25 mg/mL for 1 minute combined with temporary nasal tarsorrhaphy
Number of subjects: 20
Study 17057794 — intervention group
Group type: COMPARATOR
Intervention: No mitomycin (control group)
Number of subjects: 20
Study 17057794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin group
Number of subjects: 20
Study 12271112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) self-help manual in six modules
Number of subjects: 117
Study 12271112 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (WLC)
Number of subjects: 117
Study 9932566 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined HRT
Number of subjects: 235
Study 9932566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 235
Study 7792546 — intervention group
Group type: COMPARATOR
Intervention: Multimodal cognitive-behavioural treatments (MMCBT) with psychologist as a coach (Group A)
Number of subjects: 66
Study 7792546 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal cognitive-behavioural treatments (MMCBT) with direct psychologist contact (Group B)
Number of subjects: 66
Study 1706610 — intervention group
Group type: EXPERIMENTAL
Intervention: LNH-84 regimen
Number of subjects: 361
Study 1706610 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell ML
Number of subjects: 361
Study 1706610 — intervention group
Group type: COMPARATOR
Intervention: B-cell ML
Number of subjects: 361
Study 558548 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg daily
Number of subjects: 24
Study 558548 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg daily
Number of subjects: 24
Study 558548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31298337 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐31 overexpression
Number of subjects: 54
Study 31298337 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐31 restoration
Number of subjects: 54
Study 31298337 — intervention group
Group type: COMPARATOR
Intervention: Declined miR‐31 expressions
Number of subjects: 54
Study 28217935 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise program
Number of subjects: 90
Study 28217935 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90
Study 25442342 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mm GTV expansion
Number of subjects: 49
Study 25442342 — intervention group
Group type: COMPARATOR
Intervention: 3-mm GTV expansion
Number of subjects: 49
Study 25442342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 23063461 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-towards-positive (ATP) condition
Number of subjects: 37
Study 23063461 — intervention group
Group type: COMPARATOR
Intervention: Attention-training-control (ATC) condition
Number of subjects: 37
Study 21907058 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 400
Study 21907058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 19090439 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective radical dissection of regional lymph nodes
Number of subjects: 0
Study 19090439 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery, adjuvant treatment, or radiotherapy
Number of subjects: 0
Study 19090439 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-based control of metastases
Number of subjects: 0
Study 16533348 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer-specific training program combining strength and technique exercises for 10 weeks
Number of subjects: 20
Study 16533348 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 14654574 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzymes
Number of subjects: 0
Study 14654574 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 14654574 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-II antagonists
Number of subjects: 0
Study 14654574 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 14654574 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 0
Study 14654574 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 0
Study 10736077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnelled catheters
Number of subjects: 0
Study 10736077 — intervention group
Group type: COMPARATOR
Intervention: Untunnelled catheters
Number of subjects: 0
Study 9168214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine (10 mg in 20 mL normal saline)
Number of subjects: 112
Study 9168214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular bupivacaine (20 mL 0.5% with epinephrine)
Number of subjects: 112
Study 9168214 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine (10 mg in 1 mL)
Number of subjects: 112
Study 9168214 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL IA normal saline + 1 mL SC normal saline)
Number of subjects: 112
Study 8063651 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg/day; n = 6)
Number of subjects: 12
Study 8063651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study 2646850 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5-2.0 mg/kg i.v. combined with diazepam 0.2 mg/kg i.v.)
Number of subjects: 30
Study 2646850 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (3.0-4.0 mg/kg i.v. combined with diazepam 0.2 mg/kg i.v.)
Number of subjects: 30
Study 2646850 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 2646850 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 30
Study 5460838 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study 5460838 — intervention group
Group type: COMPARATOR
Intervention: Average Western diet (Control)
Number of subjects: 0
Study 31721909 — intervention group
Group type: EXPERIMENTAL
Intervention: Shadow examiner
Number of subjects: 415
Study 31721909 — intervention group
Group type: COMPARATOR
Intervention: Fixed examiner
Number of subjects: 415
Study 28412598 — intervention group
Group type: EXPERIMENTAL
Intervention: Glottal fry
Number of subjects: 36
Study 28412598 — intervention group
Group type: EXPERIMENTAL
Intervention: Yawn-sigh
Number of subjects: 36
Study 28412598 — intervention group
Group type: COMPARATOR
Intervention: Control group (no facilitating techniques)
Number of subjects: 36
Study 25896115 — intervention group
Group type: EXPERIMENTAL
Intervention: LA Sprouts nutrition, cooking and gardening intervention
Number of subjects: 364
Study 25896115 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire scales
Number of subjects: 364
Study 23993773 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT) program
Number of subjects: 40
Study 23993773 — intervention group
Group type: COMPARATOR
Intervention: Nonsleep-related parent education (Comparison group)
Number of subjects: 40
Study 21273301 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment for Women with Alcohol Addiction (EWA)
Number of subjects: 200
Study 21273301 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 200
Study 20387350 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (0.35 mg/kg)
Number of subjects: 30
Study 20387350 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram (1.5 mg/kg)
Number of subjects: 30
Study 20387350 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 30
Study 17084675 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst embryo transfer
Number of subjects: 0
Study 17084675 — intervention group
Group type: COMPARATOR
Intervention: Cleavage-stage embryo transfer
Number of subjects: 0
Study 15481278 — intervention group
Group type: EXPERIMENTAL
Intervention: S/FP 50/100 microg bd (n = 78)
Number of subjects: 150
Study 15481278 — intervention group
Group type: COMPARATOR
Intervention: FP 100 microg bd (n = 72)
Number of subjects: 150
Study 15481278 — intervention group
Group type: EXPERIMENTAL
Intervention: S/FP
Number of subjects: 150
Study 11529248 — intervention group
Group type: EXPERIMENTAL
Intervention: phVEGF165 gene transfer (1, 2, or 4 mg)
Number of subjects: 192
Study 11529248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 8963126 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified staircase method (Landolt rings in eight positions, scaled by a factor 1.26, PC monitor with 1024 x 768 pixels, distance 4.5 m)
Number of subjects: 102
Study 8963126 — intervention group
Group type: COMPARATOR
Intervention: DIN 58,220 method
Number of subjects: 102
Study 1467377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (n = 7)
Number of subjects: 13
Study 1467377 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 13
Study 3909956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime monotherapy
Number of subjects: 100
Study 3909956 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus flucloxacillin
Number of subjects: 100
Study 30485501 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 50 mg for 7 days
Number of subjects: 635
Study 30485501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study 28594629 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to therapist and patient (FbTP)
Number of subjects: 206
Study 28594629 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to therapist (FbT)
Number of subjects: 206
Study 28594629 — intervention group
Group type: COMPARATOR
Intervention: No feedback (NFb)
Number of subjects: 206
Study 26950661 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-module instruction
Number of subjects: 39
Study 26950661 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-demonstration approach
Number of subjects: 39
Study 25628082 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 90
Study 25628082 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Maxillary Expansion (SME)
Number of subjects: 90
Study 25628082 — intervention group
Group type: COMPARATOR
Intervention: Control - Edgewise therapy only
Number of subjects: 90
Study 22271197 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal attainment scaling (GAS)
Number of subjects: 0
Study 19289991 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Perfusion (MP)
Number of subjects: 74
Study 19289991 — intervention group
Group type: COMPARATOR
Intervention: Cold Storage (CS)
Number of subjects: 74
Study 17766699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab alone (1000 mg administered intravenously on days 1 and 15)
Number of subjects: 161
Study 17766699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus cyclophosphamide (750 mg administered intravenously on days 3 and 17)
Number of subjects: 161
Study 17766699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus methotrexate
Number of subjects: 161
Study 17766699 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone (10-25 mg/wk)
Number of subjects: 161
Study 17766699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (all groups)
Number of subjects: 161
Study 15077929 — intervention group
Group type: COMPARATOR
Intervention: CYFRA 21-1 in F0 expressed in ng/mg TP
Number of subjects: 93
Study 15077929 — intervention group
Group type: COMPARATOR
Intervention: NSE in both fractions expressed in ng/mg TP
Number of subjects: 93
Study 15077929 — intervention group
Group type: COMPARATOR
Intervention: SCC in F1 expressed in ng/mg TP
Number of subjects: 93
Study 15077929 — intervention group
Group type: COMPARATOR
Intervention: TPA in F0 expressed in mU/mg TP
Number of subjects: 93
Study 15077929 — intervention group
Group type: COMPARATOR
Intervention: TPS in both fractions expressed in mU/mg TP
Number of subjects: 93
Study 11229833 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral vitamin K1
Number of subjects: 109
Study 11229833 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of one dose of acenocoumarine
Number of subjects: 109
Study 9848299 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated partial thromboplastin time (aPTT) before conception
Number of subjects: 261
Study 9848299 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin time (PT) before conception
Number of subjects: 261
Study 9848299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen before conception
Number of subjects: 261
Study 10634921 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT 15 mmol/h
Number of subjects: 8
Study 10634921 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT 30 mmol/h
Number of subjects: 8
Study 10634921 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT 15 mmol/h
Number of subjects: 8
Study 10634921 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 2091170 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent visual feedback during abduction of the fifth digit
Number of subjects: 39
Study 2091170 — intervention group
Group type: COMPARATOR
Intervention: No feedback during thumb flexion
Number of subjects: 39
Study 2091170 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback during thumb flexion
Number of subjects: 39
Study 674355 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting neuroleptic drugs (fluphenazine decanoate, flupenthixol decanoate, fluspirilene)
Number of subjects: 97
Study 31977446 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial pivot TKA designs (Advance® II MP, GMK® Sphere, MRK, Evolution® MP, SAIPH®)
Number of subjects: 6310
Study 31977446 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance® II MP
Number of subjects: 6310
Study 31977446 — intervention group
Group type: EXPERIMENTAL
Intervention: GMK® Sphere
Number of subjects: 6310
Study 31977446 — intervention group
Group type: EXPERIMENTAL
Intervention: MRK
Number of subjects: 6310
Study 31977446 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolution® MP
Number of subjects: 6310
Study 31977446 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIPH®
Number of subjects: 6310
Study 31977446 — intervention group
Group type: COMPARATOR
Intervention: Cruciate-retaining TKA designs
Number of subjects: 6310
Study 30795731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (5 µg and 2.5 µg)
Number of subjects: 6000
Study 30795731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study 27819215 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary iron intake
Number of subjects: 7634
Study 27819215 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal dietary iron intake
Number of subjects: 7634
Study 27819215 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 7634
Study 25564476 — intervention group
Group type: EXPERIMENTAL
Intervention: glucagon‐like peptide (GLP‐1, 0.5 pmol·kg(‐1)·min(‐1))
Number of subjects: 10
Study 25564476 — intervention group
Group type: EXPERIMENTAL
Intervention: glucose‐dependent insulinotropic polypeptide (GIP, 1.5 pmol·kg(‐1)·min(‐1))
Number of subjects: 10
Study 25564476 — intervention group
Group type: COMPARATOR
Intervention: saline [control (CON)]
Number of subjects: 10
Study 23388113 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 9306
Study 23388113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 9306
Study 23388113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9306
Study 20939064 — intervention group
Group type: COMPARATOR
Intervention: Placebo compliance (high compliance defined as taking 80% or more of dispensed study medication)
Number of subjects: 3169
Study 20939064 — intervention group
Group type: COMPARATOR
Intervention: Placebo compliance (high compliance)
Number of subjects: 3169
Study 19335707 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6140 90 mg twice daily
Number of subjects: 984
Study 19335707 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6140 180 mg twice daily
Number of subjects: 984
Study 19335707 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 984
Study 19335707 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6140 (combined groups)
Number of subjects: 984
Study 16710253 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril (stepwise antihypertensive therapy)
Number of subjects: 60
Study 16710253 — intervention group
Group type: COMPARATOR
Intervention: Hypotensive drugs (standard treatment)
Number of subjects: 60
Study 14724662 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost telephone-based intervention
Number of subjects: 1632
Study 14724662 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-based intervention
Number of subjects: 1632
Study 14724662 — intervention group
Group type: COMPARATOR
Intervention: Usual care intervention
Number of subjects: 1632
Study 11344882 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselors CARE (C‐CARE) (n = 150)
Number of subjects: 460
Study 11344882 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and Support Training (CAST) (n = 155)
Number of subjects: 460
Study 11344882 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control (n = 155)
Number of subjects: 460
Study 9165168 — intervention group
Group type: EXPERIMENTAL
Intervention: Zatebradine (ULFS 49 CL)
Number of subjects: 0
Study 9165168 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7955818 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg mofegiline
Number of subjects: 24
Study 7955818 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg mofegiline
Number of subjects: 24
Study 7955818 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg mofegiline
Number of subjects: 24
Study 7955818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3539524 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Jugular (IJ) route
Number of subjects: 66
Study 3539524 — intervention group
Group type: COMPARATOR
Intervention: Subclavian (SC) route
Number of subjects: 66
Study 3539524 — intervention group
Group type: EXPERIMENTAL
Intervention: Second catheters placed over a guidewire
Number of subjects: 66
Study 3539524 — intervention group
Group type: EXPERIMENTAL
Intervention: Second catheters placed at a new site
Number of subjects: 66
Study 3539524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IJ and SC routes
Number of subjects: 66
Study 3539524 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard, sterile-insertion technique and catheter-maintenance protocol
Number of subjects: 66
Study 29504258 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rhEPO for 2 weeks
Number of subjects: 16
Study 29504258 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rhEPO for 3 days
Number of subjects: 16
Study 29504258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28328396 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Health intervention
Number of subjects: 91
Study 28328396 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 91
Study 25052783 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 285
Study 25052783 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 285
Study 22118014 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate non-occlusal implant loading
Number of subjects: 60
Study 22118014 — intervention group
Group type: COMPARATOR
Intervention: Early non-occlusal implant loading
Number of subjects: 60
Study 21092504 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (coronary angiography within 24 h of randomization)
Number of subjects: 815
Study 21092504 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (coronary angiography over 36 h after randomization)
Number of subjects: 815
Study 18503257 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical and chemical protection sunscreen (octocrylene, Parsol 1789, titanium dioxide, Mexoryl SX, Mexoryl XL)
Number of subjects: 4
Study 18503257 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical opaque material
Number of subjects: 4
Study 18503257 — intervention group
Group type: COMPARATOR
Intervention: Nonprotected areas after UVR exposure
Number of subjects: 4
Study 15681904 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy and adhesiolysis
Number of subjects: 72
Study 12591757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic dialysis
Number of subjects: 61
Study 12591757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal insufficiency (CRI)
Number of subjects: 61
Study 12591757 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 61
Study 10543576 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 125
Study 10543576 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-deficient diet
Number of subjects: 125
Study 10543576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadmium exposure
Number of subjects: 125
Study 10543576 — intervention group
Group type: COMPARATOR
Intervention: Zinc supplementation
Number of subjects: 125
Study 8823102 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 80
Study 8823102 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated surfaces
Number of subjects: 80
Study 8823102 — intervention group
Group type: COMPARATOR
Intervention: Roller pump (uncoated circuits)
Number of subjects: 80
Study 8823102 — intervention group
Group type: COMPARATOR
Intervention: Roller pump (heparin-coated circuits)
Number of subjects: 80